Assay Launch!
Revvity just announced their latest kit launch for April!! With research areas spanning oncology, inflammation, and protein-protein interactions, be sure to check them out: Revvity's Newest Assay Kits
Assay Technology | Therapeutic Area | Targets | |
| Oncology |
| |
Inflammation |
| ||
| Oncology |
| |
![]() | Inflammation |
| |
| Oncology |
| |
Inflammation |
| ||
Protein-Protein Interactions |
| ||
Whether you're familiar with Revvity's no-wash immunoassays or are looking to streamline your current workflow, our portfolio has expanded to support more specific pathway interrogation across therapeutic areas:
🔬 Oncology Signaling:
Our latest AlphaLISA SureFire Ultra and HTRF assays cover key targets involved in cell cycle control, oncogenic drivers, and transcriptional regulation.
AlphaLISA SureFire Ultra:
- Ki-67
- Src
- HRAS
- NRAS
- EGR1 (Biotin-Free)
HTRF:
- FOXM1: Total & Phospho (Thr600)
🎯 Targeted Oncology & Precision Medicine:
These new AlphaLISA SureFire Ultra kits support direct monitoring of clinically relevant oncogenic alterations.
AlphaLISA SureFire Ultra:
- EGF Receptor E746A-750 Deletion
- BCR-ABL1 fusion proteins: Total & Phospho (Tyr245); (Tyr412)
🧬DNA Damage Response (DDR):
The latest addition to our AlphaLISA SureFire Ultra DDR portfolio supports research focused on genomic instability, DNA repair mechanisms, and response to genotoxic stress.
AlphaLISA SureFire Ultra:
- H2AX (Mouse): Total & Phospho (Ser139)
🧫 STAT Signaling & Immunology:
Discover highly sensitive, no-wash workflows for STAT signaling for AlphaLISA SureFire Ultra and HTRF, as well as our first-ever STAT complex kit! Our AlphaLISA IL-12p70 kit supports inflammation and immune-response studies.
AlphaLISA:
- IL-12p70 (Mouse)
AlphaLISA SureFire Ultra:
- pSTAT1(Tyr701)-pSTAT2 (Tyr690) Complex
- STAT2: Total & Phospho (Tyr690)
HTRF:
- STAT2: Total & Phospho (Tyr690)
If any of these targets are on your radar, or if you're interested in learning more about Revvity's immunoassays, please feel free to reach out to Ashish Chougule (Ashish.Chougule@Revvity.com).
Written by Juliette Seremak, Ph.D.
Commercial Technical Writer (Drug Discovery Reagents), Revvity
Images
Additional Info
Media Contact : Ashish Chougule
Related Links : Ashish.Chougule@Revvity.com




